The Republic of Zimbabwe becomes the nineteenth (19e) An African Union (AU) member state will sign the Treaty Establishing the African Medicines Agency (AMA) on March 16, 2021, at the AU Commission in Addis Ababa, Ethiopia. The AMA Treaty was adopted by Heads of State and Government during their 32nd Ordinary session of the Assembly on February 11, 2019 in Addis Ababa, Ethiopia.
Speaking at the official signing of the Treaty, HE Amira Elfadil Mohammed, Commissioner for Health, Humanitarian Affairs and Social Development, African Union Commission, who received the Zimbabwe delegation, underlined the importance of the establishment of AMA in order to improve the production and harmonization of pharmaceuticals on the continent. She noted that the impending COVID-19 pandemic is an opportunity to accelerate the establishment of AMA and it is a top priority for the Commission to bridge the gap in the pharmaceutical industries. Zimbabwe’s Ambassador to Ethiopia and to the African Union HE Taonga Mushayavanhu reiterated the importance of WADA in synchronizing pharmaceutical systems by establishing a control mechanism for counterfeit medicines on the continent. In addition, he pledged to move quickly to the next stage of ratification of the AMA Treaty.
The signing of the Treaty is a step forward in the realization of the creation of the African Medicines Agency (AMA) resulting from the will of the Heads of State and Government to use continental institutional, scientific and regulatory resources to improve access to safe, efficient and regulatory resources. quality drugs. This is in addition to the establishment of the Harmonization of Medicines Regulation in Africa (AMRH) in 2009, under the leadership and direction of the African Union Development Agency – the New Partnership for Development. of Africa (AUDA-NEPAD) in collaboration with the regional economic communities recognized by the AU (REC) and regional health organizations (RHO), to facilitate the harmonization of regulatory requirements and practices between national authorities Medicines (ARNM) from AU Member States. In addition, motivated by the aspiration to meet internationally acceptable standards and to provide a favorable regulatory environment for pharmaceutical research and development, local production and trade between countries on the African continent.
WADA will designate, promote, strengthen, coordinate and monitor among others the Regional Centers of Regulatory Excellence (RCORE) with a view to building the capacity of medical product regulatory professionals. The agency will also coordinate and collaborate, as necessary and on a regular basis, the inspection of drug manufacturing sites, including regulatory oversight and medical product safety oversight, as determined by States Parties and / or WADA, and will make the reports available to States Parties. WADA will also promote cooperation, partnership and the recognition of regulatory decisions, in support of regional structures and national drug regulatory authorities (ANRM), which take into account the mobilization of financial and technical resources to ensure the sustainability of the drug. WADA.
The African Medicine Agency will enter into force once ratified by fifteen African Union member states. To date, the instruments of ratification have been deposited by six Member States with the Commission.